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Abstract
Experimental arthritis models are considered valuable tools for
delineating mechanisms of inflammation and autoimmune
phenomena. Use of microarray-based methods represents a
new and challenging approach that allows molecular dissection
of complex autoimmune diseases such as arthritis. In order to
characterize the temporal gene expression profile in joints from
the reactivation model of streptococcal cell wall (SCW)-induced
arthritis in Lewis (LEW/N) rats, total RNA was extracted from
ankle joints from naïve, SCW injected, or phosphate buffered
saline injected animals (time course study) and gene expression
was analyzed using Affymetrix oligonucleotide microarray
technology (RAE230A). After normalization and statistical
analysis of data, 631 differentially expressed genes were sorted
into clusters based on their levels and kinetics of expression
using Spotfire®  profile search and K-mean cluster analysis.
Microarray-based data for a subset of genes were validated
using real-time PCR TaqMan®  analysis. Analysis of the
microarray data identified 631 genes (441 upregulated and 190
downregulated) that were differentially expressed (Delta > 1.8,
P  < 0.01), showing specific levels and patterns of gene
expression. The genes exhibiting the highest fold increase in
expression on days -13.8, -13, or 3 were involved in chemotaxis,
inflammatory response, cell adhesion and extracellular matrix
remodelling. Transcriptome analysis identified 10 upregulated
genes (Delta > 5), which have not previously been associated
with arthritis pathology and are located in genomic regions
associated with autoimmune disease. The majority of the
downregulated genes were associated with metabolism,
transport and regulation of muscle development. In conclusion,
the present study describes the temporal expression of multiple
disease-associated genes with potential pathophysiological
roles in the reactivation model of SCW-induced arthritis in Lewis
(LEW/N) rat. These findings improve our understanding of the
molecular events that underlie the pathology in this animal
model, which is potentially a valuable comparator to human
rheumatoid arthritis (RA).
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Introduction
Rheumatoid arthritis (RA) is an autoimmune chronic inflam-
matory disease of unknown aetiology that is characterized
by infiltration of monocytes, T cells and polymorphonuclear
cells into the synovial joints. The pathogenesis of this dis-
ease is still poorly understood, and fundamental questions
regarding the precise molecular nature and biological sig-
nificance of the inflammatory changes remain to be
answered [1,2]. A powerful way to gain insight into the
molecular complexity and pathogenesis of arthritis has
arisen from oligonucleotide-based microarray technology
[3], because this platform provides an opportunity to ana-
lyze simultaneously the expression of a large number of
genes in disease tissues.
The earliest preclinical stages of human RA are not easily
accessible to investigation, but a diverse range of experi-
mental arthritis models are considered valuable tools for
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delineating mechanisms of inflammation and autoimmune
phenomena. An animal model that shares some of the hall-
marks of human RA is the reactivation model of streptococ-
cal cell wall (SCW)-induced arthritis in rats. In this model, a
synovitis with maximal swelling at 24 hours is induced by
local injection of SCW antigen directly into an ankle joint.
The initial response is reactivated by systemic (intravenous)
challenge with SCW, which produces a more prolonged
and severe inflammation confined to the joint previously
injected with SCW. In contrast to some other animal mod-
els, in which the arthritic response develops gradually and
unpredictably, in this model the flare response develops
synchronously, allowing precise analysis of pathophysio-
logical mechanisms [4,5].
Some pathological changes observed in SCW-induced
arthritis that are of relevance to human RA include infiltra-
tion of polymorphonuclear cells, CD4+ T cells and macro-
phages, hyperplasia of the synovial lining layer, pannus
formation and moderate erosion of cartilage and bone [4].
Previous reports have shown the dependency of this model
on tumour necrosis factor (TNF)-α, IL-1α, IL-4, P-selectin,
vascular cell adhesion molecule-1, macrophage inflamma-
tory protein (MIP)-2, MIP-1α and monocyte chemoattract-
ant protein (MCP)-1 [6,7]. Although the involvement of
nitric oxide synthase (NOS) [8] and cyclo-oxygenase [9] in
the development of SCW-induced arthritis has also been
noted, a global analysis of coordinated gene expression
during the time course of disease in this experimental arthri-
tis model has not been investigated.
Arthritis involves many cell types from tissues adjacent to
the synovium. Therefore, as shown in previous studies
[10,11], analysis of gene expression profiles by processing
whole homogenized joints can provide useful information
about dysregulated genes, not only in synoviocytes but also
in other, neighbouring cells (myocytes, osteocytes and
chondrocytes) that may also contribute to disease
pathology.
In the present study, whole homogenized rat ankle joints
from naïve, SCW-injected and phosphate-buffered saline
(PBS; vehicle)-injected animals, included in a time-course
study, were analyzed for differential gene expression using
the RAE230A Affymetrix GeneChip® microarray (Affymetrix
Inc., Santa Clara, CA, USA). In order to identify different
patterns of gene expression during the course of SCW-
induced arthritis, a selected set of genes whose expression
was statistically significantly different between arthritic and
control animals on days -13.8, -13 and 3 were analyzed
using agglomerative hierarchical clustering, Spotfire®
(Spotfire Inc., Cambridge, MA, USA) profile search and K-
means cluster analysis. Validation of microarray data for a
subset of genes was performed by real-time RT-PCR Taq-
Man® (Applied Biosystems, Foster City, CA, USA) analysis,
which provides a highly accurate method for quantifying
mRNA expression levels for any particular differentially
expressed gene. To further investigate the possible associ-
ation of 20 selected upregulated genes with arthritis patho-
genesis, their chromosomal locations and the
chromosomal locations of their corresponding human
orthologue were compared with the locations of previously
reported quantitative trait loci (QTLs) for inflammation,
arthritis and other autoimmune diseases. Our findings
show, for the first time, the gene expression profiles and
kinetics of expression of hundreds of genes that are differ-
entially expressed in arthritic joints from the reactivation
model of SCW-induced arthritis in Lewis (LEW/N) rat,
thereby improving our understanding of the biological path-
ways that contribute to the pathogenesis of arthritis in this
animal model and providing a valuable comparator to
human RA.
Methods
Reagents
The peptidoglycan–polysaccharide (PG-PS) 100p fraction
of SCW was purchased from Lee Laboratories (Grayson,
GA, USA). RAE230A Affymetrix GeneChip®  were pur-
chased from Affymetrix Inc. All reagents required for RT-
PCR were from PE Applied Biosystems (Warrington, UK).
Forward and reverse primers were purchased from Invitro-
gen™ Life Technologies (Invitrogen Ltd, Paisley, UK). Taq-
Man® probes were synthesized by PE Applied Biosystems.
RiboGreen, used to quantify RNA, was obtained from
Molecular Probes Inc. (Leiden, The Netherlands) and RNA
6000 Nano LabChip Kit®, used to assess RNA integrity,
was from Agilent Technologies Inc. (Stockport, UK).
Animals
All in vivo studies were undertaken in certified, dedicated
in vivo experimental laboratories at the GlaxoSmithKline
Medicines Research Centre (Stevenage, UK). The studies
complied with national legislation and with local policies on
the care and use of animals, and with related codes of prac-
tice. Male Lewis (LEW/N) rats obtained from Harlan UK Ltd
(Oxon, UK), at age 6–7 weeks, were housed under stand-
ard conditions and received food and water ad libitum. Ani-
mals were habituated to the holding room for a minimum of
1 week before the experimental procedures.
Induction and assessment of SCW-induced arthritis
SCW arthritis was induced in 6- to 8-week-old male Lewis
(LEW/N) rats (weight 125–150 g) following a method sim-
ilar to that previously described by Esser and coworkers
[4]. A SCW preparation (PG-PS, 100p fraction) was sus-
pended in PBS and 10 µl of the suspension containing 5
µg PG-PS from Streptococcus pyogenes was injected into
the right ankle joint (day -14). Animals from control groups
were injected similarly with 10 µl PBS. A group of nonin-
jected rats was also included in our study to assess geneAvailable online http://arthritis-research.com/content/7/1/R101
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expression profiles in joints from naïve animals. Reactiva-
tion of the arthritic inflammation was induced 14 days after
intra-articular injection (designated day 0) by intravenous
injection of 200 µg PG-PS. This resulted in monoarticular
arthritis involving the joint originally injected with PG-PS
[7]. Ankle swelling at different time points was measured
using a caliper. The inflammatory response is expressed as
the change in ankle diameter relative to the starting diame-
ter. Five animals injected with PG-PS or PBS were killed at
different time points (4 hours after intra-articular injection
[day -13.8], day -13, day -10, day 0, 6 hours after intrave-
nous challenge [day 0.4], day 1, day 3 and day 7) and ankle
joints were dissected, snap frozen in liquid nitrogen and
stored at -80°C for subsequent analysis.
Total RNA isolation from rat joints
Frozen ankle joints were pulverized in liquid nitrogen using
a mortar and pestle, and total RNA was isolated from indi-
vidual homogenized joints (four or five animals/group) using
RNeasy® Mini-kits (Qiagen Ltd, Crawley, UK), following the
manufacturer's instructions. In our experimental design, a
nonpooling strategy for total RNA samples was used (a
total of 75 samples from different animals were analyzed).
In order to ensure that no contamination with genomic DNA
occurred, samples were treated for 15 min with 10 units of
RNase-free DNase (Qiagen Ltd) at room temperature.
RiboGreen® RNA Quantitation Kit (Molecular Probes Inc.)
with optical densities at 260 nm and 280 nm was used to
determine the total RNA concentration of the samples. The
quality of the RNA was assessed based on demonstration
of distinct intact 28S and 18S ribosomal RNA bands using
RNA 6000 Nano LabChip Kit® (Agilent 2100 Bioanalyser;
Agilent Technologies UK Ltd, Stockport, UK). Five of the 75
total RNA samples exhibited evidence of RNA degradation
and were excluded from subsequent analyses.
Oligonucleotide microarray analysis
The rat RAE230A GeneChip® oligonucleotide microarray
(Affymetrix Inc.), containing about 16,000 probe sets, rep-
resenting 4699 well annotated full-length genes, 10,467
expressed sequence tags (ESTs) and 700 non-ESTs
(excluding full lengths), was used to analyze gene expres-
sion profiles in joints from SCW-injected or PBS-injected
animals during the course of disease. Isolated total RNA
(10 µg/chip) was used to generate biotin-labelled cRNA.
Aliquots of each sample (n = 70) were then hybridized to
RAE230A Affymetrix GeneChip® arrays at 45°C for 16
hours, followed by washing and staining, in accordance
with the standard protocol described in the Affymetrix
GeneChip® Expression Analysis Technical Manual [12].
The GeneChip®s were scanned using the Affymetrix 3000
Scanner™ and the expression levels were calculated for all
16,000 probe sets (about 12,000 genes) with Affymetrix®
MicroArraySuite software (MAS 5.0).
Statistical analysis of microarray data
The Affymetrix GeneChip® data were processed, normal-
ized and statistically analyzed (analysis of variance
[ANOVA]) using Rosetta Resolver® v3.2 software (Rosetta
Biosoftware, Kirkland, WA, USA). Genes with P < 0.01
(ANOVA) were considered to be differentially expressed.
Fold changes in gene expression were calculated by divid-
ing the mean intensity signal from all the individual SCW-
injected rats included in each group by the mean intensity
signal from the corresponding PBS control group. The level
of statistical significance was determined by ANOVA. Sub-
sequent data analysis involved two-dimensional data visu-
alization, principal component analysis (PCA) using
SIMCA-P v10.2 Statistical Analysis Software (Umetrics,
Windsor, UK) [13] and agglomerative hierarchical cluster-
ing analysis [14]. For identification of different temporal pat-
terns and levels of gene expression, Spotfire®  profile
search analysis and K-means clustering analysis [15] were
performed using the Spotfire® DecisionSite for Functional
Genomics programme. In this analysis the mean signal
intensity of gene expression in each group included in the
study (four to five samples/group) was used. Identification
of the ontology, accession number and chromosomal loca-
tion of the genes of interest was performed combining
information from GlaxoSmithKline Bioinformatics Data-
bases and other existing public databases http://
www.ncbi.nlm.nih.gov. The mapping of the differentially
expressed genes to QTLs for arthritis was investigated
using Rat and Human Genome browsers from Ensembl
http://www.ensembl.org/, Rat Genome Database http://
rgd.mcw.edu and the ARB Rat Genetic Database http://
www.niams.nih.gov/rtbc/ratgbase/.
Quantitative real-time PCR (TaqMan®)
Expression levels of selected genes found to be upregu-
lated by gene array analysis were validated by real-time RT-
PCR TaqMan®  analysis using the ABI Prism 7900
Sequence Detector System®  (PE Applied Biosystems,
Foster City, CA, USA), as previously described [16]. For
cDNA synthesis 600 ng total RNA (from the same samples
analysed by RAE230A GeneChip®  microarray) were
reverse transcribed using TaqMan®  RT reagents (PE
Applied Biosystems) in a MJ Research PTC-200 PCR Pel-
tier Thermal Cycler (MJ Research, Rayne Brauntree, Essex,
UK).
TaqMan® probes and primers for the genes of interest were
designed using primer design software Primer Express™
(PE Applied Biosystems) and optimized for use. The for-
ward primers, reverse primers and probes used are sum-
marized in Table 1. The final optimized concentrations of
forward primer, reverse primer and probe for all of the tar-
get genes were 900 nmol/l, 900 nmol/l and 100 nmol/l,
respectively, except for CD14, for which the concentra-
tions were 300 nmol/l, 300 nmol/l and 100 nmol/l.Arthritis Research & Therapy    Vol 7 No 1    Rioja et al.
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Standard curves for each individual target amplicon were
constructed using sheared rat genomic DNA (BD Bio-
sciences, Cowley, Oxford, UK). All PCR assays were per-
formed in duplicate, and results are represented by the
mean values of copy no./50 ng cDNA. Ubiquitin [17] was
used as a housekeeping gene against which all samples
were normalized.
Data presentation
The data included in Table 2 show the mean fold change
(Delta) increase or decrease in gene expression in joints
from SWC-injected rats compared with the expression in
the corresponding PBS control group, along with the P
value. As selection criteria to present the most relevant
genes, a cutoff of 1.8-fold increased/decreased expression
and P < 0.01 were arbitrarily chosen. Gene expression pro-
file plots (Fig. 6) represent data from Affymetrix Rat
Genome RAE230A GeneChip®  and real-time RT-PCR
TaqMan® as the mean of signal intensity or the mean of nor-
malized copy no./50 ng cDNA for all the samples from the
same group (four to five), respectively.
Results
Time course of inflammation in the SCW-induced 
arthritis model
Intra-articular injection of SCW resulted in increased ankle
swelling that peaked 24 hours after injection (day -13), fol-
lowed by a gradual reduction by day 0 (Fig. 1). At this time
point intravenous challenge with SCW led to reactivation of
the inflammatory response, which peaked 72 hours there-
after (day 3). Animals injected intra-articularly with PBS
(vehicle in which the SCW was suspended) were used as
control groups at each specific time point. Another group
of naïve animals (noninjected rats) was used to assess a
possible inflammatory response due to the intra-articular
injection alone.
Gene expression profiling in SCW-induced arthritis
Analysis of RAE230A GeneChip® microarray data identi-
fied about 9000 probes (5479 upregulated and 3898
downregulated) that were differentially expressed to a
highly significant degree (P < 0.01) in arthritic rat joints
from the time course study. After applying selection criteria
(Delta > 1.8 and P < 0.01), 631 of the dysregulated probes
had well characterized full-length sequences in databases
(441 upregulated and 190 downregulated) and 697 were
Table 1
TaqMan® probes and primers for the genes of interest
Gene of interest Forward primer Reverse primer Probe
IL-1β 5'-CACCTCTCAAGCAGAGCACAG 5'-GGGTTCCATGGTGAAGTCAAC 5'-6-FAM-TGTCCCGACCATTGCTGTTTCCTAGG-TAMRA
IL-6 5'-CAAGACCATCCAACTCATCTTG 5'-CACAGTGAGGAATGTCCACAAAC 5'-6-FAM-TCGGCAAACCTAGTGTGCTATGCCTAAGCA-TAMRA
TNF-α 5'-CCAGGTTCTCTTCAAGGGACAA 5'-CTCCTGGTATGAAATGGCAAATC 5'-6-FAM-CCCGACTATGTGCTCCTCACCCACA-TAMRA
GRO1 5'-TGTGTTGAAGCTTCCCTTGGA 5'-TGAGACGAGAAGGAGCATTGGT 5'-6-FAM-TGTCTAGTTTGTAGGGCACAATGCCCT-TAMRA
CD14 5'-GGACGAGGAAAGTGTCCGCT 5'-AGGTACTCCAGGCTGCGACC 5'-6-FAM-TTCTATGCGCGGGGGCGGAA-TAMRA
CD3 5'-GGATGGAGTTCGCCAGTCAA 5'-GGTTTCCTTGGAGACGGCTG 5'-6-FAM-ACAGGTCTACCAGCCCCTCAAGGACCG-TAMRA
Ubiquitin 5'-CGAGAACGTGAAGGCCAAGA 5'-GGAGGACAAGGTGCAGGGTT 5'-6-FAM-CCCCTGACCAGCAGAGGCTCATCTTTG-TAMRA
IL, interleukin; TNF, tumour necrosis factor.
Figure 1
Schematic representation of the experimental design for the time  course study in the reactivation model of streptococcal cell wall  (SCW)-induced arthritis in Lewis (LEW/N) rats Schematic representation of the experimental design for the time 
course study in the reactivation model of streptococcal cell wall 
(SCW)-induced arthritis in Lewis (LEW/N) rats. The inflammatory 
response is represented as the change in ankle diameter (mm) relative 
to the starting diameter. Data are expressed as means ± standard error 
(four to five animals/group). Intra-articular (i.a.) injection of SCW 
resulted in increased ankle swelling that peaked 24 hours after injection 
(day -13) followed by a gradual reduction by day 0. At this time point, 
intravenous (i.v.) challenge with SCW led to reactivation of the inflam-
matory response, which peaked 72 hours thereafter (day 3). Animals 
injected with a suspension of SCW (continuous line) in PBS or with 
PBS alone (dashed line; five animals/group) were killed on the days 
indicated, and joints taken and processed for gene expression profiling 
analysis and mRNA quantification by GeneChip® microarray and real-
time RT-PCR TaqMan®, respectively. A group of naïve noninjected ani-
mals (n = 4) was also included in the study to assess basal expression 
levels of the analyzed genes.Available online http://arthritis-research.com/content/7/1/R101
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Table 2
Genes upregulated in ankle joints from SCW-induced arthritis in Lewis (LEW/N) rats
Accession no. Gene name Day -13.8 Day -13 Day 3 C I
Delta P Delta P Delta P
Angiogenesis
NM_030985 AGTR1 _ _ _ _ 4.0 2.3E-05 7 L
AI639162 ANGPT1 _ _ _ _ 1.8 8.5E-08 7 L
NM_031012 ANPEP _ _ _ _ 2.2 2.9E-18 7 M
AI101782 COL18A1 _ _ _ _ 2.9 6.3E-26 7 L
AI170324 FIGF _ _ 1.6 9.4E-04 2.4 4.6E-11 6 L
NM_012620 SERPINE1 6.6 2.3E-06 _ _ 27.6 0.0E+00 4 L
Cell adhesion
NM_012830 CD2 _ _ 2.1 2.9E-04 _ _ 3 L
NM_054001 CD36L2 _ _ _ _ 2.6 5.4E-05 7 L
AF065147 CD44 2.1 2.1E-08 1.6 1.1E-03 _ _ 2 M
BE108345 COL12A1 _ _ _ _ 2.5 4.6E-43 7 M
AI172281 COL5A2 _ _ _ _ 2.0 9.3E-06 7 H
NM_021760 COL5A3 _ _ _ _ 3.1 6.9E-27 7 M
AF084544 CSPG2 2.3 2.4E-03 2.1 5.8E-04 8.9 7.2E-37 5 L
NM_053719 EMB _ _ _ _ 3.5 1.7E-19 7 L
NM_053634 FCNB 8.7 3.0E-28 8.0 1.1E-17 29.0 0.0E+00 5 M
AI236745 GALNT1 _ _ _ _ 2.9 0.0E+00 7 L
NM_133298 GPNMB _ _ 2.2 3.6E-12 2.5 0.0E+00 6 H
NM_012967 ICAM1 8.9 0.0E+00 4.4 7.2E-09 4.0 2.2E-11 5 L
AF268593 ITGAM 2.0 2.6E-03 3.8 1.7E-15 6.4 3.3E-18 5 L
BI296880 ITGB3 1.5 7.0E-03 _ _ 2.1 2.3E-03 4 L
AF003598 ITGB7 2.0 8.9E-14 1.6 1.2E-03 1.9 1.1E-06 5 L
U56936 KLRB1B _ _ _ _ 3.0 6.4E-03 7 L
NM_022393 MGL _ _ 2.1 7.3E-08 2.1 2.3E-11 6 L
U72660 NINJ1 _ _ _ _ 1.8 6.6E-28 7 M
BE097805 PCDHGC3 _ _ 1.8 3.0E-03 _ _ 3 L
AJ299017 RET _ _ _ _ 2.8 1.6E-08 7 L
AF071495 SCARB1 _ _ _ _ 1.8 6.9E-03 7 L
L 2 5 5 2 7 S E L E __3 . 1 3 . 6 E - 0 4 __3 L
D10831 SELL 1.6 9.3E-05 _ _ 1.8 6.9E-06 4 L
BI296054 SELP 1.8 7.1E-08 1.9 2.6E-07 2.2 4.2E-13 5 L
AI176034 TNC _ _ _ _ 2.6 3.7E-26 7 M
AF159103 TNFIP6 2.2 6.2E-04 2.2 3.1E-05 5.0 1.3E-21 5 L
NM_031590 WISP2 _ _ _ _ 2.6 0.0E+00 7 MArthritis Research & Therapy    Vol 7 No 1    Rioja et al.
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Chemotaxis
NM_053619 C5AR1 1.6 5.0E-06 2.4 9.6E-21 2.7 2.8E-32 5 M
NM_019205 CCL11 3.9 2.3E-03 3.7 2.3E-07 _ _ 2 L
NM_057151 CCL17 2.2 1.1E-05 _ _ _ _ 1 L
AF053312 CCL20 8.3 7.3E-19 10.2 2.8E-10 15.5 3.5E-32 5 L
U22414 CCL3 15.3 1.7E-19 3.2 3.8E-05 2.1 1.1E-08 5 L
U06434 CCL4 6.0 1.5E-17 _ _ _ _ 1 L
NM_031116 CCL5 _ _ 2.6 5.9E-11 2.0 1.1E-03 6 L
NM_020542 CCR1 5.2 1.4E-15 2.1 3.0E-05 2.1 3.2E-03 5 L
NM_021866 CCR2 5.1 2.7E-07 3.3 2.9E-05 6.9 2.7E-13 5 L
NM_053960 CCR5 6.2 4.3E-19 6.0 1.8E-09 6.0 1.4E-10 5 L
D87927 CINC2 3.5 7.0E-03 _ _ _ _ 1 L
AF253065 CKLF1 3.3 6.3E-09 3.0 2.7E-07 8.2 8.6E-08 5 L
NM_022218 CMKLR1 _ _ 2.5 3.4E-03 _ _ 3 L
U22520 CXCL10 3.2 4.4E-09 2.5 9.0E-03 1.4 1.3E-03 5 L
NM_053647 CXCL2 38.7 1.6E-07 2.3 9.1E-03 2.6 1.0E-03 5 L
NM_022214 CXCL6 2.2 2.3E-04 _ _ 7.5 3.2E-06 4 L
NM_017183 CXCR2 10.6 1.5E-07 3.6 1.3E-03 _ _ 2 L
NM_053415 CXCR3_V1 _ _ _ _ 1.9 9.5E-04 7 L
AA945737 CXCR4 1.6 1.7E-03 1.7 3.9E-04 3.4 2.7E-15 5 L
NM_030845.1 GRO 17.1 0.0E+00 23.0 2.4E-04 19.8 1.8E-12 5 L
NM_053321 PTAFR _ _ 2.5 2.0E-03 _ _ 3 L
NM_031530 SCYA2 3.4 6.0E-26 3.2 1.8E-16 6.0 0.0E+00 5 M
Complement activation
D88250 C1S _ _ 1.6 4.4E-03 1.8 7.5E-22 6 M
_ C2 6.9 9.20E-42 3.5 1.28E-11 16.8 0.0E+00 5 L
NM_016994.1 C3 2.7 2.0E-10 3.0 5.4E-12 10.4 0.0E+00 5 L
AI169829 MASP1 _ _ _ _ 2.4 8.5E-08 7 L
Immune response/inflammatory response
XM_215303 RT1.S3 _ _ 2.0 0.0012 1.6 1.5E-03 6 L
AF307302 BTNL2 _ _ 2.1 1.0E-15 3.2 0.0E+00 6 M
NM_021744 CD14 2.8 7.8E-18 2.0 4.4E-06 1.7 7.3E-05 5 M
NM_012705 CD4 _ _ _ _ 1.8 1.3E-07 7 L
NM_013069 CD74 _ _ 2.2 3.5E-18 2.7 1.1E-31 6 H
NM_031538 CD8a _ _ 9.5 2.7E-03 10.9 6.2E-07 6 L
BI282755 EDG3 _ _ _ _ 2.1 5.9E-03 7 L
X73371 FCGR2 3.1 1.4E-20 3.8 2.4E-08 6.5 0.0E+00 5 L
NM_053843 FCGR3 2.2 3.3E-15 2.0 2.8E-12 2.6 0.0E+00 5 M
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NM_133624 GBP2 3.4 6.2E-35 _ _ 1.5 3.8E-06 4 L
AF176534 HFE _ _ _ _ 1.8 6.6E-03 7 L
XM_215347 HLA-DMA _ _ 2.0 1.22E-14 2.7 0.0E+00 6 L
_ HLA-DMB _ _ 2.0 5.42E-15 3.2 1.1E-13 6 M
NM_022605 HPSE _ _ _ _ 1.9 3.0E-09 7 L
NM_133533 IGB _ _ _ _ 2.9 8.4E-09 7 L
NM_053374 IGIFBP _ _ 2.2 7.2E-03 _ _ 3 L
AJ245643 IL1a 2.7 1.2E-03 _ _ _ _ 1 L
NM_031512 IL1b 22.0 1.1E-30 9.5 4.5E-15 5.7 1.6E-35 5 L
NM_053953 IL1R2 2.5 1.9E-15 _ _ _ _ 1 L
NM_022194 IL1RN 7.4 2.8E-03 _ _ _ _ 1 L
NM_012589 IL6 10.0 7.3E-17 20.7 7.9E-04 21.4 5.5E-17 5 L
NM_013110 IL7 _ _ _ _ 2.8 2.4E-04 7 L
NM_012591 IRF1 2.9 4.7E-13 2.6 2.8E-08 3.3 2.0E-13 5 L
NM_130741 LCN2 2.4 1.7E-09 3.4 9.8E-12 13.2 0.0E+00 5 M
BF282471 LCP2 2.6 2.2E-04 3.3 2.4E-04 6.2 4.4E-06 5 L
NM_022634 LST1 4.9 6.2E-14 6.3 6.4E-14 16.7 2.0E-36 5 L
NM_031634 MEFV 2.7 1.9E-07 _ _ 1.9 7.4E-05 4 L
X52711 MX1 _ _ 2.8 4.9E-07 1.9 2.1E-15 6 L
NM_134350 MX2 _ _ 2.9 5.9E-04 _ _ 3 L
NM_053734 NCF1 _ _ 2.0 9.4E-16 2.0 3.7E-06 6 L
AA858801 NFKB1 2.1 1.1E-12 _ _ _ _ 1 M
AW672589 NFKBIA 2.5 5.2E-36 _ _ _ _ 1 M
L12562 NOS2A 6.0 1.9E-05 _ _ _ _ 1 L
Z18877 OAS1 1.6 8.4E-06 2.4 3.8E-06 1.8 3.7E-06 5 L
NM_053288 ORM1 _ _ 2.0 7.0E-04 3.1 9.8E-19 6 L
NM_031713 PIRB 2.4 3.9E-06 2.5 2.6E-06 3.3 7.6E-10 5 L
AF349115 PPBP _ _ _ _ 3.2 8.5E-03 7 L
NM_080767 PSMB8 1.5 3.0E-03 2.3 2.0E-09 3.3 0.0E+00 5 L
AI599350 PSMB9 2.0 2.0E-07 2.1 7.4E-09 3.7 2.3E-25 5 L
AB048730 PTGES 8.2 8.1E-40 3.9 1.0E-04 2.4 6.7E-04 5 L
NM_012645 RT1Aw2 _ _ 3.3 0.000334 5.4 2.7E-10 6 L
X57523.1 TAP1 1.6 2.8E-04 1.6 9.8E-03 2.4 5.6E-07 5 L
NM_021578 TGFB1 _ _ 2.1 8.4E-06 2.6 1.7E-10 6 L
AA819227 TNF 11.1 1.3E-27 2.5 1.9E-04 _ _ 2 L
BM390522 TNFRSF1b 14.3 8.2E-19 3.7 4.2E-06 8.0 3.5E-06 5 L
NM_012759 VAV1 4.6 7.1E-05 7.6 1.2E-07 10.8 1.2E-12 5 L
Proteolysis and peptidolysis
NM_024400 ADAMTS1 3.1 9.2E-16 2.1 7.0E-04 3.5 1.3E-16 5 L
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AA849399 CTSZ 1.6 6.4E-08 1.5 8.9E-12 3.4 1.6E-33 5 M
NM_012582 HP 2.1 4.8E-20 _ _ 1.7 5.5E-05 4 L
NM_031670 KDAP 18.8 8.7E-23 6.6 5.0E-07 48.2 2.3E-37 5 L
AF154349 LGMN _ _ 2.1 1.8E-06 2.8 0.0E+00 6 M
NM_053963 MMP12 _ _ 4.1 8.6E-05 7.7 8.2E-13 6 L
M60616.1 MMP13 _ _ _ _ 2.0 4.7E-08 7 M
X83537 MMP14 _ _ _ _ 1.8 2.1E-17 7 H
NM_053606 MMP23A _ _ _ _ 2.1 1.6E-11 7 L
NM_133523 MMP3 2.9 5.7E-29 2.7 1.4E-12 9.3 0.0E+00 5 H
AI102069 NSF _ _ 1.7 8.1E-03 1.8 3.9E-04 6 L
BF549923 PCSK5 _ _ 1.8 1.5E-03 3.4 7.5E-21 6 L
X63434 PLAU _ _ _ _ 1.8 2.9E-14 7 M
AF007789 PLAUR 6.2 4.6E-04 _ _ 4.9 7.2E-03 4 L
NM_053372 SLPI 2.6 8.3E-09 2.6 5.4E-22 7.0 0.0E+00 5 M
NM_053819 TIMP1 2.2 0.0E+00 1.8 5.9E-09 6.4 0.0E+00 5 H
NM_053299 UBD _ _ _ _ 4.7 9.1E-04 7 L
Signal transduction
NM_019285 ADCY4 _ _ _ _ 2.3 3.5E-05 7 L
BF285345 ARRB2 _ _ 1.8 2.5E-05 2.5 6.5E-20 6 L
NM_057196 BAIAP2 _ _ 4.4 5.5E-03 _ _ 3 L
NM_012766 CCND3 _ _ _ _ 2.1 6.0E-08 7 L
NM_013169 CD3d _ _ _ _ 3.9 3.7E-07 7 L
AF065161 CISH 2.5 1.1E-03 _ _ _ _ 1 L
NM_031352 DBNL _ _ 1.7 6.6E-11 1.8 1.2E-04 6 L
BI278868 EPIM _ _ _ _ 2.1 6.7E-03 7 L
NM_024147 EVL _ _ _ _ 3.6 8.0E-09 7 L
L02530 FZD2 _ _ _ _ 3.3 6.3E-07 7 L
NM_030829.1 GPRK5 _ _ _ _ 2.0 1.0E-04 7 L
U87863.1 HGS _ _ 1.9 3.6E-03 _ _ 3 L
AY044251 IL13RA1 _ _ _ _ 3.2 3.0E-08 7 L
AI178808 IL2RG 2.4 8.1E-14 2.5 10.0E-23 5.6 0.0E+00 5 L
NM_133380 IL4R _ _ 6.5 4.8E-05 7.5 3.4E-18 6 L
NM_017020 IL6R _ _ 1.8 2.4E-10 1.8 1.6E-12 6 L
NM_019311 INPP5D _ _ _ _ 1.9 7.9E-20 7 L
NM_012798 MAL 2.1 1.9E-04 _ _ _ _ 1 L
AW533194 MAPK10 2.4 5.7E-03 _ _ _ _ 1 L
AF411318 MT1A 2.6 2.4E-27 2.4 2.2E-04 3.4 6.0E-34 5 M
NM_012613 NPR1 _ _ _ _ 3.3 1.9E-03 7 L
U32497 P2RX4 _ _ 1.6 4.2E-15 1.9 2.5E-20 6 L
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AF202733 PDE4B 2.4 1.1E-07 2.5 8.1E-04 2.3 2.5E-03 5 L
BE099769 PLAA _ _ 2.5 8.7E-03 _ _ 3 L
X04440 PRKCB1 _ _ _ _ 1.8 3.3E-08 7 L
AF254800 RAB0 _ _ _ _ 1.9 7.8E-04 7 L
NM_019250 RALGDS 1.9 8.1E-05 _ _ _ _ 1 L
NM_021661 RGS19 _ _ _ _ 1.8 1.8E-05 7 L
AF321837 RGS2 _ _ _ _ 2.3 2.4E-09 7 L
NM_053338 RRAD 7.0 5.2E-05 4.8 1.6E-05 4.0 6.5E-03 5 L
BE117558 SFRP1 _ _ _ _ 1.8 2.4E-08 7 M
BF389682 SOCS3 3.8 0.0E+00 2.0 1.2E-05 3.6 3.2E-33 5 L
NM_022230 STC2 _ _ 3.1 2.2E-03 _ _ 3 L
BG668493 STMN2 _ _ 2.3 2.6E-06 14.0 7.2E-42 6 L
U21683 SYK _ _ _ _ 1.8 2.1E-05 7 L
Genes upregulated (Delta > 1.8 and P < 0.01) on days -13.8 (4 hours after intra-articular injection of streptococcal cell wall [SCW]), -13 and 3 
are grouped by their general ontology and clustered based on their similarity in terms of pattern of expression (C) and expression level (I). Data are 
expressed as the mean fold increase in gene expression (Delta) in SCW-injected animals as compared with expression in the corresponding 
phosphate-buffered saline (PBS) control group (four to five animals/group), along with the P value. C, number of clusters to which the gene 
corresponds (trend plots are given in Fig. 6); I, intensity of gene expression (L = low intensity [0–500], M = medium intensity [500–1500], H = 
high intensity [1500–4000]). A line (_) in the Delta or P cell indicates that the gene was not found to be differentially expressed at that particular 
time point.
Table 3
Upregulated genes (Delta > 5, P < 0.01) not previously reported to be associated with arthritis
Accession no. Gene Delta Rat CL Rat QTLs Human CL Human QTLs
NM_178144 AMIGO3 Nd/Nd/5.9 8q32 Cia6 3p21.31 Asthma
NM_130411 CORO1A 3.1/2.7/6.6 1q36 Pia11 16p12.1 Blau syndrome, asthma
NM_024381 GYK 6.7/Nd/Nd Xq22 Cia19 Xp21.3 Allergic rhinitis
NM_031670 KDAP 18.8/6.6/48.2 1q22 _ 19q13.3 Asthma, SLE, MS, SD
NM_569105 LCP2 2.6/3.3/6.2 10q12 Cia16, Pia15 5q33.1 RA, PDB, asthma, IBD, psoriasis, ATD
NM_021586 LTBP2 Nd/Nd/6.5 6q31 Pia3, Pia24 14q24 SLE, MODY3
NM_198746 Ly-49.9 Nd/2.0/5.6 4q42 Cia13, Cia24, Pia7, Pia23, Oia2, 
Oia7, Oia8, Ciaa4
12p13-p12 RA, allergic rhinitis, hypophosphataemic rickets
NM_022667 MATR1 1.7/1.9/5.7 8q32 Cia6 3q21 Atopic dermatitis, asthma, psoriasis
NM_133306 OLR1 8.3/2.8/3.7 4q42 Cia13, Cia24, Pia7, Pia23, Oia2, 
Oia7, Oia8, Ciaa4
12p13.2-p12.3 RA, hypophosphataemic rickets, allergic rhinitis
NM_053687 SLFN4 5.8/4.6/4.8 10q26 Cia16, Cia21, Cia22, Cia23, Oia4, 
Ciaa2
17q11.2-q21.1 SLE, MS
The rat chromosomal location and the chromosomal locations of the corresponding human orthologue were identified and mapped to quantitative 
trait loci (QTLs) previously associated with inflammation, arthritis and/or other autoimmune diseases. Delta values are given for the following time 
points: day -13.8/day -13/day 3. ATD, autoimmune thyroid disease; CIA, type II collagen-induced arthritis; Ciaa, CIA autoantibody; CL, chromosome 
location; IBD, inflammatory bowel disease; MOYD 3, maturity-onset diabetes of the young 3; MS, multiple sclerosis; Nd, not differentially expressed; 
Oia, oil-induced arthritis; PDB, Paget's disease of bone; PIA, pristane-induced arthritis; RA, rheumatoid arthritis; SD, spondylocostal dysostosis; 
SLE, systemic lupus erythematosus.
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unknown (ESTs; 444 upregulated and 253 downregu-
lated). These genes are too numerous to describe in detail,
and therefore we present a selected list of upregulated
genes in Table 2 and Fig. 2, and a selection of downregu-
lated genes based on the ontologies that reflect the major
changes occurring in arthritic animals (Fig. 3). ESTs were
excluded from Table 2 and from subsequent clustering
analysis. See Additional file 1, which contains all genes that
were upregulated and downregulated.
Principal component analysis and hierarchical clustering
An overview of the experimental RAE230A GeneChip®
data was obtained using PCA (graphs not shown) [13] and
agglomerative hierarchical clustering [14]. Both two-
dimensional analyses identified day -13.8 (4 hours after
intra-articular injection of SCW), day -13 and day 3 as the
time points at which the greatest changes in gene expres-
sion in arthritic joints occurred in comparison with corre-
sponding PBS control groups. The results from the
hierarchical clustering are shown for visual inspection as a
coloured heat map in Fig. 4. As shown on the x-axis (panel
at the top of Fig. 4), the majority of the PBS samples clus-
tered together, except the PBS samples from day -13.8,
which clustered close to the SCW-injected animals from
day 3. This observation indicated the presence of a mild
inflammatory response in joints from rats killed 4 hours after
the initial intra-articular injection of PBS, when compared
with expression levels in joints from naïve animals or the
PBS samples from later time points.
PCA and hierarchical clustering analysis allowed us to
identify two outliers corresponding to arthritic animals from
day 3, which did not show any sign of measurable inflam-
mation after intravenous challenge. Both samples were
excluded from subsequent mean or Delta calculations.
Identification of different patterns of gene expression
The selected 631 dysregulated genes (P < 0.01 and Delta
> 1.8) were analyzed using Spotfire® profile search analy-
sis and K-means clustering [15], allowing the identification
of different patterns and levels of gene expression through-
out the time course of disease. As shown in Fig. 5, the
upregulated genes were grouped into seven clusters (C-1
to C-7) according to their kinetics of expression. Thus, all
genes exhibiting similar patterns of expression at the ana-
lyzed time points were grouped into the same cluster (e.g.
C-1 for those genes whose expression reached a peak on
day -13.8). These genes were also sorted into three K-
means clusters according to their level of expression (low,
medium and high). The cluster number to which each gene
belongs is summarized in Table2.
Interestingly, the expressions of different markers for cell
types associated with the pathogenesis of RA were found
to be upregulated throughout the time course of SCW-
induced arthritis. These markers were grouped into
different clusters as follows: C-2 = CD44 (leucocytes,
erythrocytes); C-3 = CD2 (T cell, natural killer [NK] cells),
E-selectin (SELE; activated endothelial cells); C-4 = L-
selectin (SELL; lymphocytes, monocytes and NK cells); C-
5 = CD14 (monocytes), ICAM1 (endothelial cells), α M
integrin (ITGAM or CD11b; granulocytes, monocytes, NK
cells), P-selectin (SELP; endothelial cells, activated
platelets), lipocalin 2 (LCN2; neutrophils); C-6 = CD74 (B
cells, monocytes), CD38 (activated T cells, plasma cells),
CD8a (cytotoxic/suppressor T cells, NK cells); and C-7 =
Figure 2
Representative graph of genes that were upregulated (Delta > 1.8 and P < 0.01) in arthritic joints from streptococcal cell wall (SCW)-induced arthri- tis model on day -13.8 (4 hours after systemic challenge), day -13 and day 3 Representative graph of genes that were upregulated (Delta > 1.8 and P < 0.01) in arthritic joints from streptococcal cell wall (SCW)-induced arthri-
tis model on day -13.8 (4 hours after systemic challenge), day -13 and day 3. The graphs represent the fold increase in gene expression (Delta) and 
the name of the genes associated with the following ontologies: apoptosis (A; red bars), regulation of cell cycle and cell proliferation (B; blue bars), 
transport (C; green bars) and regulation of transcription, DNA-dependent (D; yellow bars).Available online http://arthritis-research.com/content/7/1/R101
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Figure 3
Downregulated genes (Delta < -1.8 and P < 0.01) in arthritic joints from streptococcal cell wall (SCW)-induced arthritis model on day 3 after sys- temic challenge Downregulated genes (Delta < -1.8 and P < 0.01) in arthritic joints from streptococcal cell wall (SCW)-induced arthritis model on day 3 after sys-
temic challenge. This graph shows the fold decrease in gene expression (Delta) on day 3 and the name of the downregulated genes associated with 
the following ontologies: metabolism (E; red bars), regulation of muscle development (F; blue bars) and transport (G; green bars).
Figure 4
Heat map diagram of differential gene expression in joints from the time course study in the streptococcal cell wall (SCW)-induced arthritis in Lewis  (LEW/N) rat Heat map diagram of differential gene expression in joints from the time course study in the streptococcal cell wall (SCW)-induced arthritis in Lewis 
(LEW/N) rat. Gene expression data were obtained using Affymetrix Rat Genome RAE230A GeneChip®. The cluster diagram represents 631 differ-
entially expressed probes with P < 0.01 and Delta > 1.8. Each column represents a single joint tissue and each row represents a single gene. 
Expression levels are coloured green for low intensities and red for high intensities (see scale at the top left corner). At the top of the cluster diagram 
is an enlarged panel including the names and hierarchical clustering order of the individual samples analyzed. Red names are joint tissues from 
SCW-injected animals, indicating the corresponding time point of sample collection, and blue names are the samples from the phosphate-buffered 
saline (PBS) control groups. As shown, the major changes in gene expression occurred in samples corresponding to arthritic animals from days -
13.8 (4 hours after intra-articular injection of SCW), -13 and 3. N, naïve animals.Arthritis Research & Therapy    Vol 7 No 1    Rioja et al.
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CD3d (T cells), CD4 (helper–inducer T cells). The different
temporal expression of these markers highlights that
expression levels for CD3d and CD4 were significantly
upregulated only at day 3 after challenge, in contrast to
CD2 and E-selectin, whose expression was found to be
upregulated only at day -13. The rest of the markers exhib-
ited significant fold changes in gene expression at both
phases of disease (4 hours after intra-articular injection of
SCW, day -13 and day 3 after challenge), except CD8a,
CD74 and CD38, which were found to be upregulated at a
later time point in the pre-reactivation phase (day -13). Only
CD44 was not found to be upregulated on day 3 after chal-
lenge. Lipocalin 2, αM integrin and CD8a exhibited the
greatest fold changes in gene expression.
Functional grouping of dysregulated genes
In order to establish functional annotations for the selected
dysregulated genes, the biological processes and molecu-
lar functions of the genes were investigated using different
databases. This search identified 19 ontologies for the
upregulated genes, allowing us to organize them according
to their major functions (Table 2 and Fig. 2). Because of
space limitations in the manuscript, we could not include all
of the upregulated genes in Table 2 and Fig. 2. The genes
not included were involved in blood coagulation, catabo-
lism, defence response, G-protein-coupled receptor pro-
tein signalling pathways, metabolism and protein
modification, or were genes with unknown functions (for
more information, please see Additional file 1). A hallmark
of RA is infiltration of leucocytes into synovial tissue medi-
ated by a complex network of cytokines, adhesion mole-
cules and chemoattractants [18].
Interestingly, most of the genes exhibiting the greatest fold
increase in gene expression (Delta > 5) on days -13.8, -13
or 3 were involved in chemotaxis. These included several
CC chemokine ligands (CCLs; CCL20, CCL2 [also called
SCYA2 or MCP-1]), CXC chemokine ligands (CXCLs;
Figure 5
Temporal gene expression profiles in the reactivation model of streptococcal cell wall (SCW)-induced arthritis in rat identified using Spotfire® profile  search analysis Temporal gene expression profiles in the reactivation model of streptococcal cell wall (SCW)-induced arthritis in rat identified using Spotfire® profile 
search analysis. The seven different clusters identified are termed C-1 to C-7. Each graph shows the characteristic pattern of expression throughout 
the time course of disease for a representative gene from the defined cluster. Results are expressed as the mean of the signal intensity of gene 
expression for each group (four to five samples/group). The number of the cluster to which each gene belongs is included in Table 2. The time 
course of inflammation, expressed as change in ankle diameter (mm) relative to the starting diameter, is shown in the upper left panel. N, naïve; PBS, 
phosphate-buffered saline.Available online http://arthritis-research.com/content/7/1/R101
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CXCL2, CXCL6 and GRO1), CC chemokine receptors
(CCRs; CCR1, CCR2, CCR5), CXC chemokine receptors
(CXCRs; CXCR2) and a recently characterized cytokine
called chemokine-like factor 1 [19].
Our results also showed marked upregulation (Delta > 5)
for numerous genes that are involved in the immune and/or
inflammatory response, such as IL-1β, IL-6, TNF-α,
TNFRSF1b, IL-1Rn, NOS2, CD8a, VAV1, LST1 (leukocyte
specific transcript 1), LCP2 (lymphocyte cytosolic protein
2), FCGR2 (Fc receptor, IgG, low affinity Iib), PTGES
(microsomal prostaglandin E synthase-1) and the major his-
tocompatibility complex (MHC) class Ib gene (RTAW2).
Other components of the MHC such as MHC class II (HLA-
DMA and HLA-DMB) and MHC class Ib RT1.S3 genes
were also found to be upregulated in this model. Genes
participating in cell adhesion such as TNFIP6, FCNB (fico-
lin B), CSPG2 (versican), ICAM1 and αM integrin (ITGAM)
also exhibited a significant fold increase in gene expression
(Delta > 5). Among other genes, some mediators control-
ling extracellular matrix (ECM) turnover and breakdown
under normal and disease conditions, including five matrix
metalloproteinases (MMPs; MMP-3, -12, -13, -14 and -
23a), the aggrecanase ADAMTS-1, tissue inhibitor of met-
alloproteinases (TIMP)1, and the secretory leucocyte pro-
tease inhibitor (SLPI) were also found to be significantly
upregulated in arthritic joints. The majority of the downreg-
ulated genes were associated with regulation of metabo-
lism, myogenesis, or regulation of muscle development and
transport (Fig. 3).
Differentially expressed genes: QTL association
From the 441 selected genes that were upregulated during
SCW-induced arthritis, we selected a list of 20 genes that
exhibited a greater than fivefold change in gene expression
and that had not previously been linked to autoimmune
arthritis. To further investigate the possibility that these
genes play a role in arthritis pathogenesis, their rat chromo-
somal locations and the locations of their human ortho-
logues were identified and compared with those of rat and
human QTLs for autoimmune diseases. Interestingly, 10 of
these genes were found to be located in chromosomal
regions that mapped to rat and/or human QTLs previously
reported to be associated with inflammation, arthritis, or
autoimmune diseases, such as systemic lupus erythemato-
sus, multiple sclerosis, allergic rhinitis and asthma (Table
3).
Analysis of expression profiles of specific transcripts
In order to validate microarray data, mRNA expression lev-
els for a subset of genes were quantified by real-time RT-
PCR TaqMan® analysis. As shown in Fig. 6, there was a
Figure 6
Confirmation of the expression levels of six of the highly differentially expressed genes highlighted in Table 2 by real-time RT-PCR TaqMan® analysis Confirmation of the expression levels of six of the highly differentially expressed genes highlighted in Table 2 by real-time RT-PCR TaqMan® analysis. 
The graphs compare the gene expression profiles for IL-1β, tumour necrosis factor (TNF)-α, IL-6, GRO1, CD14 and CD3 obtained using two differ-
ent methods: Affymetrix Rat Genome RAE230A GeneChip® (filled squares) and real-time RT-PCR TaqMan® analysis (open squares). Data are 
expressed as the mean of signal intensity or the mean of copy no./50 ng cDNA normalized against the housekeeping gene ubiquitin, for all of the 
samples from the same group (four to five). The Pearson product moment correlation coefficient (r) for each comparison is given. PBS, phosphate-
buffered saline; SCW, streptococcal cell wall.Arthritis Research & Therapy    Vol 7 No 1    Rioja et al.
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significant correlation (Pearson product moment correla-
tion coefficient r > 0.9 and P < 0.01) between the gene
expression profiles for the proinflammatory cytokines IL-1β,
TNF-α and IL-6, the chemokine GRO1 and the cell markers
CD14 and CD3, when microarray data were compared
with RT-PCR TaqMan® data. Although the fold changes in
gene expression calculated using data from both methods
were not exactly the same (probably due to differences in
the sensitivities of the assays), the quantitative real-time RT-
PCR TaqMan® method verified the results of the gene array
analysis.
Discussion
The temporal expression of multiple disease-associated
genes with potential pathophysiological roles in the reacti-
vation model of SCW-induced arthritis in Lewis (LEW/N)
rat has not previously been fully addressed. The present
study analyzed gene expression profiles in rat joints with
SCW-induced arthritis using RAE230A GeneChip® oligo-
nucleotide microarray (Affymetrix Inc.). We chose to profile
gene expression in whole ankle joint tissues, which com-
prises heterogeneous cell types, with the aim of gaining a
global insight into the molecular changes associated with
arthritis pathology in this model. Analysis of the time course
data generated by microarray identified 631 genes (441
upregulated and 190 downregulated) with full-length
sequences in databases that were significantly differentially
expressed (Delta > 1.8 and P < 0.01). Our experimental
design (time course study) and use of K-means cluster
analysis allowed us to identify specific patterns of gene
expression for the different dysregulated genes,
highlighting the importance of performing kinetic studies to
identify the time point at which a particular gene is maxi-
mally expressed. Thus, these gene expression data indicate
optimal times for measuring potential disease biomarkers in
rat joints, and our approach offers a useful tool with which
to investigate the clinical efficacy and mechanism of action
of novel therapeutic agents in rat SCW-induced arthritis.
Changes in gene expression may reflect regulation at the
mRNA level or changes in the number of cells (proliferation
or infiltration) that synthesize these mRNAs. Thus, opti-
mally, microarray analysis should be conducted in isolated
populations of cells so that differential gene expression
may be directly correlated with transcription of the genes.
However, complex diseases such as RA involve extensive
tissue injury, and not all of the cell types that contribute to
RA pathogenesis have been identified. Hence, analysis of
the damaged tissue, rather than analysis of an isolated cell
type, increases the probability that differential gene expres-
sion will be examined in those cells that are important in RA
pathogenesis. In the present study we conducted a global
analysis of coordinated gene expression in injured tissue.
Further bioinformatic analysis of the data to examine cell
markers, and genes whose expression may correlate with
them, in combination with analysis of the cell populations
present in the arthritic joint using immunohistochemistry or
fluorescence activated cell sorting techniques, would be
required to corroborate the differential gene expression of
a particular gene of interest. Previous studies have already
shown that cell-specific gene expression patterns can indi-
cate the presence of immune cells [20]. RAE230A Gene-
Chip®  oligonucleotide microarray analysis identified the
expression of different markers for cell types associated
with the pathogenesis of RA. Based on the level of gene
expression and Delta values detected for the different
markers, our results suggest that the main cell types
present in arthritic joints in this model are T cells, neu-
trophils, monocytes/macrophages and B cells, confirming
previous descriptions of the joint cell composition in this
model [6,21].
Gene expression profiling of arthritic rat joints revealed a
spectrum of genes exhibiting extensive inflammatory activ-
ity, infiltration of activated cells, angiogenesis, regulation of
apoptosis and ECM remodelling activities. Most of the
genes found to be upregulated in SCW-induced arthritic
joints have also been reported to be highly expressed in
human RA synovial tissue [22,23] or in joints from other
rodent experimental arthritis models [10,11,24,25]. The
upregulated expression of TNF-α, IL-1α, IL-1β, IL-4R, P-
selectin, MIP-1α (CCL3), MCP-1 (CCL2), NOS2 and
NOS3 [6-8] demonstrated in the present study is in agree-
ment with previous observations of the dependency of the
rat SCW-induced arthritis model on these mediators. The
SLPI has previously been reported to be upregulated in
arthritic joints and to mediate tissue destruction and inflam-
mation in a rat model of arthritis induced by intraperitoneal
injection of SCW [26]. Similar results were found in our
study, because significant upregulation of SLPI gene
expression was observed during both phases of the dis-
ease. Additionally, previous studies have shown that
nuclear factor-κB (NF-κB) is activated in the synovium of
rats with SCW-induced arthritis and that inhibition of the
activity of this transcription factor enhances synovial apop-
tosis, which is consistent with the potential involvement of
NF-κB in synovial hyperplasia [27]. In accord with these
observations, the microarray data showed early upregula-
tion of genes involved in the NF-κB signalling pathway,
such as NF-κB1 (p50 or p105), NFKBIA (IκBα), TNF-α,
TNFRSF1a and TNFRSF1b, suggesting a possible regula-
tory role of NF-κB in the transcription of genes that mediate
disease progression in SCW-induced arthritis.
Histopathological studies in arthritic rat joints from the
reactivation SCW-induced arthritis model have shown that
only moderate histological changes in articular cartilage,
with few erosive effects on bone, occur at early stages in
the flare reaction (day 3), whereas evident cartilage degra-
dation is observed at later time points (20 days after intra-Available online http://arthritis-research.com/content/7/1/R101
R115
venous challenge with SCW) [4]. The microarray data
suggest that tissue remodelling is an active process in this
model because abundant expression of collagen-related
genes (Col5A2, Col5A3, Col12A1 and Col18A1),
enzymes that degrade matrix molecules such as MMPs and
the aggrecanase ADAMTS-1 (a disintegrin-like and
metalloproteinase with thrombospondin type 1 motif, which
is capable of cleaving versican), together with other genes
that control ECM turnover and breakdown (TIMP1, PLAU
[plasminogen activator, urokinase], PLAU receptor
[PLAUR]), were found to be upregulated in arthritic joints.
MMP-3 (stromelysin) appears to be pivotal in the activation
of collagenases, whereas MMP-13 is crucial in collagen
breakdown [28]. The PLAU/PLAUR system plays a critical
role in cartilage degradation during osteoarthris by regulat-
ing pericellular proteolysis mediated by serine proteases
[22,29]. The complement system has also been reported to
participate in tissue injury during inflammatory and autoim-
mune diseases [30], and ficolins can initiate the lectin path-
way of complement activation through attached serine
proteases (Mannan-binding lectin serine proteases
[MASPs]) [31]. Interestingly, the microarray data revealed
significant upregulation of the first complement component
C1, which exerts collagenolytic activity in addition to the
role it plays in the classic cascade [29]. In addition,
upregulation of the expression of C2, C3, ficolin B (FCNB)
and MASP1 was also noted, supporting the concept that
activation of the complement system, together with the
imbalance between MMPs, TIMPs and other related mole-
cules, could mediate cartilage destruction in this experi-
mental model of RA.
In our analysis we also identified 10 genes that are differen-
tially expressed in arthritic joints and that that map to
genomic regions previously reported to be QTLs for
autoimmune diseases. Although it is premature to suggest
that the 10 genes are candidates for these QTLs, our
observations suggest that expression of these genes may
influence the onset, severity and/or susceptibility to arthritis
in this animal model. Of particular interest is KDAP (napsin)
because of the high fold increase in gene expression
observed in arthritic joints from SCW-injected animals (D =
48.2 on day 3). This aspartic protease was shown to be
expressed in kidney, lung and lymphoid organs of mice
[32], and it has been suggested that it functions as a lyso-
somal protease involved in protein catabolism in renal prox-
imal tubules [33]. However, little is known about the role of
KDAP in other organs and tissues. Interestingly, human
KDAP resides on chromosome 19q13.3–19q13.4, a
region previously identified to be involved in susceptibility
to autoimmune diseases, including systemic lupus ery-
thematosus, multiple sclerosis and insulin-dependent dia-
betes mellitus [34,35]. Our results show, for the first time,
that KDAP gene expression is upregulated in experimental
arthritis tissue, and suggest that further characterization is
required to unravel the biological/pathological activities of
this gene in RA.
The microarray data also revealed high upregulation in runt-
related transcription factor 1 (RUNX1) and a group of
transporter genes (SLC11A1, SLC13A3, SLC1A3,
SLC21A2 [MATR1], SLC28A2, SLC29A3, SLC5A2 and
SLC7A7), from which the prostaglandin transporter gene
MATR1 exhibited the greatest upregulation on day 3 after
intravenous challenge with SCW. The rat MATR1 gene
maps to the type II collagen induced arthritis severity QTL6
(Cia6) [36], and its human orthologue is located within
autoimmune disease QTLs for asthma, psoriasis and atopic
dermatitis [37-39]. Several authors reported linkage of
SLC11A1 (also named NRAMP1) to human RA [40-42].
The Z-DNA forming polymorphic repeat in the RUNX1-con-
taining promoter region of human SLC11A1 may contrib-
ute to the differing allelic associations observed with
infectious versus autoimmune disease susceptibility [43].
Recent studies reported that regulation of expression of
organic cation transporter gene SLC22A4 by RUNX1 is
associated with susceptibility to RA [44]. Other transporter
genes (SLC12A8 and SLC9A3R1) have also been linked
to susceptibility to other autoimmune diseases such as
psoriasis [45]. These observations together suggest that
RUNX1 and the transporter genes found to be differentially
expressed in arthritic joints may contribute to arthritis sus-
ceptibility and to the inflammatory processes that mediate
the pathology of this model.
Conclusion
The present study identified the temporal gene expression
profiles of hundreds of genes, including cytokines, chemok-
ines, adhesion molecules, transcription factors, apoptotic
and angiogenesis mediators, whose expression is associ-
ated with onset and progression of arthritis pathology in rat
joints from the reactivation model of SCW-induced arthritis
in Lewis (LEW/N) rat. This transcript profiling offers not
only the optimal kinetics of expression for different potential
disease biomarkers, but it also improves our understanding
of the molecular events that underlie the pathology in this
animal model of RA. In addition, although the majority of
genes found to be differentially expressed in this model
were previously associated with human RA, further genes
not previously linked to autoimmune diseases were identi-
fied, providing a resource for future research and for the
development of new therapeutic targets.
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